TD Private Client Wealth’s Ascendis Pharma A/S ASND Stock Holding History

TD Private Client Wealth’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$533	Hold	2	–	–	﹤0.01%	1556
2026 Q1	$457	Hold	2	–	–	﹤0.01%	1501
2025 Q4	$426	Sell	2 -71	-97%	-$14.7K	﹤0.01%	1497
2025 Q3	$14.5K	Buy	73 +71	+3,550%	+$13.2K	﹤0.01%	1030
2025 Q2	$345	Hold	2	–	–	﹤0.01%	1354
2025 Q1	$312	Buy	+2	New	+$286	﹤0.01%	1359

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TD Private Client Wealth's ASND Position: Q2 2026 in Review

TD Private Client Wealth held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 2 shares worth $533. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

TD Private Client Wealth first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. The position peaked at $14.5K in Q3 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

TD Private Client Wealth held 2 shares of Ascendis Pharma A/S worth $533 as of Q2 2026.
TD Private Client Wealth left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1556 holding.
TD Private Client Wealth first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
TD Private Client Wealth's Ascendis Pharma A/S position peaked at $14.5K in Q3 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.